We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 60,335 | 08:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 13/10/2020 09:49 | Unpleasantness | festario | |
| 13/10/2020 09:22 | ".......Subject to funding we expect a pivotal trial to start before the end of the year, and if the Phase 2 data is replicated in a larger Phase 3 study, SNG001 would be the most effective treatment for SARS-CoV-2 with future potential to treat various seasonal, endemic, and pandemic threats. We initiate coverage with a Buy rating and 990p price target.." blimey that is some (imo) rather intemperate statement....and,as someone else has pointed out,rather lets the agenda out of the bag. Incidentally.....how is the proposed/potential mkt cap of circa £1.5bn being justified here? | thefartingcommie | |
| 13/10/2020 09:06 | The calm before the storm | blakieboy7 | |
| 13/10/2020 09:01 | Ok... soon after 9amReversal was powerful, it needs to consolidate and go again.Institutional buyers will stand off, they won't chase it. | festario | |
| 13/10/2020 08:56 | 4minutes and counting festario | arab3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
